<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904904</url>
  </required_header>
  <id_info>
    <org_study_id>539</org_study_id>
    <secondary_id>2007-004686-18</secondary_id>
    <nct_id>NCT00904904</nct_id>
  </id_info>
  <brief_title>Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to show that indomethacin is at least as effective as ketorolac
      for the prevention of ocular inflammation following cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous flare</measure>
    <time_frame>Post-operative day 1 &amp; day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aqueous flare</measure>
    <time_frame>Postoperative day 30 and day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of retinal thickness</measure>
    <time_frame>Postoperative day 30 &amp; day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cataract</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin ophthalmic solution 0.1% for post-surgical inflammation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac ophthalmic solution 0.5% for post-surgical inflammation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin ophthalmic solution</intervention_name>
    <description>Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Ophthalmic Solution</intervention_name>
    <description>Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery</description>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be planning to undergo cataract surgery on one eye by
             phacoemulsification with posterior chamber intraocular lens, using topical or general
             anaesthesia.

          -  Subjects must have a preoperative flare â‰¤ 15 ph/ms, measured with a laser flare
             meter(LFM) without pharmacological pupil dilation, within the 2 months preoperatively.

        Exclusion Criteria:

          -  Subjects who have any progressive pathology requiring the use of topical or systemic
             anti-inflammatory or anti-infectious agents.

          -  Subjects who take acetylsalicylic acid at doses &gt; 100 mg daily and cannot discontinue
             usage during the study.

          -  Subjects who have a history of asthma linked to acetylsalicylic acid or other
             nonsteroidal anti-inflammatory (NSAI) drug administration.

          -  Subjects with immunodepression.

          -  Subjects with a history of intolerance to the study drug or to any NSAI drug.

          -  Subjects who are monocular for any reason other than cataract.

          -  Subjects who are treated with local or systemic anti-inflammatory drugs within 10 days
             prior to inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Brenger</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Berlin</city>
        <zip>D 13581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>August 10, 2012</last_update_submitted>
  <last_update_submitted_qc>August 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

